Technology
Health
Biotechnology

Intra-Cellular Therapies

$13.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.18 (1.35%) Today
+$0.12 (0.89%) After Hours

Why Robinhood?

You can buy or sell ITCI and other stocks, options, ETFs, and crypto commission-free!

About

Intra-Cellular Therapies Inc. Common Stock, also called Intra-Cellular Therapies, is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Read More Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

Employees
73
Headquarters
New York, New York
Founded
2013
Market Cap
742.62M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
338.86K
High Today
$13.61
Low Today
$13.36
Open Price
$13.36
Volume
106.88K
52 Week High
$23.64
52 Week Low
$10.21

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2013 IPO
US

News

Seeking AlphaMay 8

Intra-Cellular Therapies Inc. (ITCI) CEO Sharon Mates on Q1 2019 Results - Earnings Call Transcript

Intra-Cellular Therapies, Inc (NASDAQ:ITCI) Q1 2019 Earnings Conference Call May 8, 2019 8:30 AM ET Company Participants Juan Sanchez – Vice President of Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann – Executive Vice President and Chief Commercial Officer Andrew Satlin – Executive Vice President and Chief Medical Officer Larry Hineline – Senior Vice President and Chief Financial Officer Kimberly Vanover – Senior Vice President of Early Stage Clinical Development ...

51
Yahoo FinanceMay 8

Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)

The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow.

36
NasdaqMay 8

Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2019, and provided a corporate update. "2018 was an important year for ITCI and our momentum has carried over into 2019," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "Our NDA for lumateperone for the ...

4

Earnings

-$0.91
-$0.78
-$0.66
-$0.53
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.